Cagrilintide
Long-acting amylin analogue investigated in human clinical trials for weight management and metabolic disease.
Human researchExplore this ingredient →← All stacks & combinationsINGREDIENT INGREDIENT POPULAR GOALS THE COMMUNITY RATIONALE THE OPEN QUESTION CAGRILINTIDE SEMAGLUTIDE Randomised trial · combination Randomised trial · combination Trial record · REDEFINE 1
Clinical research
CagriSema
CagriSema combines cagrilintide and semaglutide for weight management and, unlike most combinations here, has been studied directly in the REDEFINE clinical programme.
Weight & Metabolism
01
THE BUILDING BLOCKS
What’s in it?
Semaglutide
GLP-1 receptor agonist with extensive human clinical research.
Extensive human researchExplore this ingredient →The ingredients listed here do not specify a particular product or mixing ratio. Pre-mixed products may differ from the formulations used in research.
02
PEOPLE & EXPERIENCE
Why this combination is discussed
CagriSema combines cagrilintide and semaglutide for weight management and, unlike most combinations here, has been studied directly in the REDEFINE clinical programme.
Weight & Metabolism
Cagrilintide and semaglutide have been studied together in the REDEFINE programme.
Human trials have tested these ingredients together. Their findings apply to the formulations and groups of people studied; other blends may differ.
Community experience can explain why a pairing has become popular. It cannot show whether the ingredients work better together or whether a mixed product is stable, accurately dosed or safe.
03
THE REASON FOR INTEREST
Why study them together?
Cagrilintide and semaglutide have been studied together in the REDEFINE programme.
How their research overlaps
Human trials have tested these ingredients together. Their findings apply to the formulations and groups of people studied; other blends may differ.
The individual profiles explain each ingredient’s potential benefits and research. Even when their effects seem complementary, studies are needed to find out whether using them together adds a benefit.
04
Direct human combination trialsWHAT THE RESEARCH CAN SUPPORT
Evidence for this combination
REDEFINE 1 and REDEFINE 2 are separate randomised trials that tested cagrilintide and semaglutide together. REDEFINE 1 studied people without type 2 diabetes; REDEFINE 2 studied people with it. Both provide evidence about the combination itself.
The REDEFINE 1 trial record and paper describe the same study, rather than two separate trials. We checked available publication details and summaries, not the full papers. This source check does not assess current regulatory approval.
Explore the sources below ↓05
RESEARCH & COMMUNITY CONTEXT
Doses & duration
Published study structure
The linked trial records and papers describe the doses and duration studied under medical supervision. They are research information, not personalised instructions.
Investigational · trial-led discussion
- Starting point discussed
- Community discussion often borrows the lowest 0.3 mg weekly phase-2 study arm. That was a randomized research dose, not a validated consumer starting amount.
- Duration / cycle
- The phase-2 dose-finding study ran for 26 weeks with structured escalation. Informal schedules cannot be assumed to reproduce that protocol.
- Continuation / break
- No authorised maintenance dose exists. The studied 0.3–4.5 mg weekly arms and CagriSema programmes belong to specific trial designs.
Published research context
- Starting point discussed
- Approved semaglutide dosing depends on the licensed product and indication; research protocols should not be treated as personalised dosing advice.
- Duration / cycle
- 68 weeks
- Continuation / break
- No evidence-based maintenance or break interval is established.
Using two ingredients in the same period and mixing them in one vial or syringe are different questions. Separate schedules cannot establish compatibility, interactions or a safe combined total.
06
WHAT REMAINS UNCERTAIN
Safety & uncertainties
- The combination needs its own safety research, including possible interactions and side effects.
- What a product contains, how it is made and how it is used all matter. Products sold under the same name may differ.
- A clinician can assess how existing medicines or health conditions affect the risks. These pages provide general information, not personal treatment advice.
07
FOLLOW THE EVIDENCE
Sources & search record
Last source check: 14 September 2026
Each link explains what it covers: the combination itself, an individual ingredient or safety information. A trial record and a paper can describe the same study.
Garvey et al., 2025 — REDEFINE 1 ↗
Studied adults with overweight or obesity who did not have type 2 diabetes.
Davies et al., 2025 — REDEFINE 2 ↗
Studied adults with overweight or obesity and type 2 diabetes.
REDEFINE 1 — ClinicalTrials.gov NCT05567796 ↗
Details of the same trial reported in the REDEFINE 1 paper.
About this search
We used targeted web searches for ingredient pairs, including searches focused on PubMed and ClinicalTrials.gov. We followed relevant papers, research reviews and FDA safety information, checking whether the ingredients were actually given together and how they were used. Some full papers were unavailable, so we relied on their published summaries. Web searches can miss studies: this was a targeted source check, not an exhaustive or systematic review, a clinical assessment or a review of UK regulation. The links below let you explore further; search results are not evidence on their own.
Search terms used
- "REDEFINE 1" "NEJMoa2502081" results 20.4
- "Cagrilintide-Semaglutide" "2502082" "1200"
- "cagrilintide" "semaglutide" REDEFINE 1 systematic review meta analysis
Search for these ingredients together:
Studies may use different names for the same ingredient. The search terms above show which alternatives we checked. Community experiences can explain interest in a stack, but we did not count anecdotes or seller claims as clinical studies.